Neuroendocrine Tumors Clinical Trials Near Me
As of October 12, 2026, 161 Neuroendocrine Tumors clinical trials are recruiting or about to open (135 recruiting now, 26 opening soon). 57 of them have at least 1 open site in the United States, across 49 states. Enter your ZIP code to see which are closest to you.
Also on Trial Friend:Neuroendocrine Tumors pageMatch Me
All 135 Neuroendocrine Tumors trials and their US sites
Enter your ZIP code above to sort them by how far their nearest open site is from you.
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsAnchorage Associates in Radiation Medicine, Anchorage, Alaska; Alaska Breast Care and Surgery LLC, Anchorage, Alaska; Alaska Oncology and Hematology LLC, Anchorage, Alaska and 376 more sitesRecruitingPhase 2Ages 18+Run by SWOG Cancer Research Network
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryMassive Bio SYNERGY-AI site, Birmingham, Alabama; Massive Bio SYNERGY-AI site, Mobile, Alabama; Massive Bio SYNERGY-AI site, Scottsdale, Arizona and 64 more sitesRecruitingRun by Massive Bio, Inc.
- Integrated Cancer Repository for Cancer ResearchAdvent Health, Greenwood Village, Colorado; Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester, Connecticut; Florida Hospital Memorial Medical Center, Daytona Beach, Florida and 39 more sitesRecruitingAges 19 to 110Run by University of Nebraska
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsThe University of Alabama at Birmingham, Birmingham, Alabama; Mayo Clinic Hospital, Phoenix, Arizona; The University of Arizona Cancer Center, Tucson, Arizona and 37 more sitesRecruitingPhase 2/3Ages 18+Run by Exelixis
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialUniversity of Alabama at Birmingham Cancer Center, Birmingham, Alabama; Mayo Clinic Hospital in Arizona, Phoenix, Arizona; Banner University Medical Center - Tucson, Tucson, Arizona and 29 more sitesRecruitingPhase 2Ages 18+Run by National Cancer Institute (NCI)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsTower Cancer Research Foundation, Beverly Hills, California; Cedars-Sinai Medical Center, Los Angeles, California; UCSF Medical Center-Mission Bay, San Francisco, California and 21 more sitesRecruitingPhase 2Ages 18+Run by National Cancer Institute (NCI)
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors23 open sitesRecruitingPhase 1/2Ages 18+Run by Crinetics Pharmaceuticals Inc.
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETMayo Clinic Arizona, Scottsdale, Arizona; Highlands Oncology Group, Fayetteville, Arkansas; Rocky Mountain Cancer Centers, Denver, Colorado and 16 more sitesRecruitingPhase 3Ages 12 to 100Run by Novartis Pharmaceuticals
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsMayo Clinic, Jacksonville, Florida; Biogenix Molecular, Miami, Florida; The University of Chicago, Chicago, Illinois and 16 more sitesRecruitingPhase 1/2Ages 18 to 90Run by Perspective Therapeutics
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenBanner MD Anderson Cancer Center, Gilbert, Arizona; Hoag Memorial Hospital Presbyterian, Newport Beach, California; Yale University - New Haven Hospital - Yale Cancer Center, New Haven, Connecticut and 14 more sitesRecruitingPhase 3Ages 18+Run by Crinetics Pharmaceuticals Inc.
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.12 open sitesRecruitingPhase 1Ages 18+Run by RayzeBio, Inc.
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California; Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois; Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville, Illinois and 7 more sitesRecruitingPhase 2Ages 12+Run by Merck Sharp & Dohme LLC
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California; UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California; Memorial Hospital East, Shiloh, Illinois and 5 more sitesRecruitingPhase 1Ages 18+Run by National Cancer Institute (NCI)
- A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyEmory University, Atlanta, Georgia; University of Chicago, Chicago, Illinois; University of Pennsylvania, Philadelphia, Pennsylvania and 1 more siteRecruitingPhase 1/2Ages 18 to 85Run by Chimeric Therapeutics
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsUniversity of Southern California, Los Angeles, California; START Midwest, Grand Rapids, Michigan; The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio and 1 more siteRecruitingPhase 1/2Ages 18+Run by Tanabe Pharma America, Inc.
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitUniversity of Michigan Hospitals, Ann Arbor, Michigan; Case Comprehensive Cancer Center, Cleveland, Ohio; Oregon Health & Science University, Portland, Oregon and 1 more siteRecruitingPhase 1Ages 18+Run by Novelty Nobility, Inc.
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsUCSF Benioff Children's Hospital, San Francisco, California; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania and 1 more siteRecruitingPhase 1Ages 24 Months to 18Run by ITM Solucin GmbH
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsCity of Hope, Duarte, California; UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California; Stanford Cancer Institute, Stanford, CaliforniaRecruitingPhase 1Ages 18 to 75Run by Anusha Kalbasi
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerMayo Clinic in Florida, Jacksonville, Florida; Altru Cancer Center, Grand Forks, North DakotaRecruitingPhase 2Ages 18+Run by Mayo Clinic
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.Emory University Hospital Midtown, Atlanta, Georgia; Emory University Hospital, Atlanta, GeorgiaRecruitingPhase 1Ages 18+Run by Emory University
New trials, status changes and new sites, straight from ClinicalTrials.gov. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Neuroendocrine Tumors. Turn any of these off from the link in every email.
Where Neuroendocrine Tumors trials are recruiting in the US
The US cities with the most Neuroendocrine Tumors trials recruiting are Bethesda, Maryland (14), Philadelphia, Pennsylvania (14), Rochester, Minnesota (10), Columbus, Ohio (9) and Nashville, Tennessee (9), counting trials with at least 1 open site in each city.
Hospitals that run trials for a rare condition often see more people with it than most clinics do, so this list can also help you find doctors who know Neuroendocrine Tumors, even if no trial fits you.
- National Institutes of Health Clinical Center
- Massive Bio SYNERGY-AI site
- National Institutes of Health ( Site 0125)
- University of Pennsylvania
- Fox Chase Cancer Center
- Children's Hospital of Philadelphia
- and 7 more
- Mayo Clinic in Rochester
- Mayo Clinic
- Mayo Clinic Cancer Center (MCCC)
- Ohio State University Comprehensive Cancer Center
- Massive Bio SYNERGY-AI site
- Ohio State University
- and 2 more
- Vanderbilt University/Ingram Cancer Center
- Henry-Joyce Cancer Clinic
- Massive Bio SYNERGY-AI site
- and 4 more
- Huntsman Cancer Institute/University of Utah
- Huntsman Cancer Institute, University of Utah
- Huntsman Cancer Institute at University of Utah
- and 2 more
- University of Chicago Comprehensive Cancer Center
- Northwestern University
- Massive Bio SYNERGY-AI site
- and 5 more
- Mayo Clinic in Florida
- Massive Bio SYNERGY-AI site
- Mayo Clinic
- and 3 more
States with at least 1 open site: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming.
Questions about finding a Neuroendocrine Tumors trial near you
Are there Neuroendocrine Tumors clinical trials near me?
As of October 12, 2026, 161 Neuroendocrine Tumors clinical trials are recruiting or about to open (135 recruiting now, 26 opening soon). 57 of them have at least 1 open site in the United States, across 49 states. Enter your ZIP code on this page to rank every one of them by the distance to its closest open site, with the sites shown on a map.
Which states have Neuroendocrine Tumors clinical trial sites?
As of October 12, 2026, recruiting Neuroendocrine Tumors trials list open sites in 49 states. The US cities with the most Neuroendocrine Tumors trials recruiting are Bethesda, Maryland (14), Philadelphia, Pennsylvania (14), Rochester, Minnesota (10), Columbus, Ohio (9) and Nashville, Tennessee (9), counting trials with at least 1 open site in each city.
What if there is no Neuroendocrine Tumors trial near me?
Some trials pay for or reimburse travel and lodging, and a few send staff or use local labs so fewer visits happen at the study site, so ask the study contact before ruling a trial out. You can also sign up on this page to get an email when a Neuroendocrine Tumors trial opens a new site or changes status.
How is the distance to a trial site measured?
Distances are straight-line miles from the center of your ZIP code to each study site's listed location, not driving distance. Your browser looks up the ZIP code's coordinates with a free map service, Zippopotam.us, and the ZIP code is never sent to or stored by Trial Friend.
FDA-approved for Neuroendocrine Tumors: Somatuline Depot (lanreotide), Lutathera (lutetium lu 177 dotatate), Xermelo (telotristat ethyl).
Source: ClinicalTrials.gov, trials with status Recruiting or Not yet recruiting. Refreshed every 6 hours; counts as of October 12, 2026. Sites that ClinicalTrials.gov lists as closed or withdrawn are left out.